4.7 Article

TSMDA: Target and symptom-based computational model for miRNA-disease-association prediction

Journal

MOLECULAR THERAPY-NUCLEIC ACIDS
Volume 26, Issue -, Pages 536-546

Publisher

CELL PRESS
DOI: 10.1016/j.omtn.2021.08.016

Keywords

-

Funding

  1. Melbourne Research Scholarship
  2. Joe White Bequest Fellowship
  3. Newton Fund RCUK-CONFAP Grant - Medical Research Council [MR/M026302/1]
  4. Wellcome Trust [093167/Z/10/Z]
  5. Jack Brockhoff Foundation [JBF 4186]
  6. National Health and Medical Research Council (NHMRC) of Australia [GNT1174405]
  7. Victorian Government's Operational Infrastructure Support Program
  8. Wellcome Trust [093167/Z/10/Z] Funding Source: Wellcome Trust
  9. MRC [MR/M026302/1] Funding Source: UKRI

Ask authors/readers for more resources

The emergence of high-throughput sequencing techniques has highlighted the importance of miRNAs in diseases, with the TSMDA machine-learning method showing superiority in predicting miRNA-disease associations. This method has the potential to uncover new associations and aid in further experimental characterization.
The emergence of high-throughput sequencing techniques has revealed a primary role of microRNAs (miRNAs) in a wide range of diseases, including cancers and neurodegenerative disorders. Understanding novel relationships between miRNAs and diseases can potentially unveil complex pathogenesis mechanisms, leading to effective diagnosis and treatment. The investigation of novel miRNA-disease associations, however, is currently costly and time consuming. Over the years, several computational models have been proposed to prioritize potential miRNA-disease associations, but with limited usability or predictive capability. In order to fill this gap, we introduce TSMDA, a novel machine-learning method that leverages target and symptom information and negative sample selection to predict miRNA-disease association. TSMDA significantly outperforms similar methods, achieving an area under the receiver operating characteristic (ROC) curve (AUC) of 0.989 and 0.982 under 5-fold cross-validation and blind test, respectively. We also demonstrate the capability of the method to uncover potential miRNA-disease associations in breast, prostate, and lung cancers, as case studies. We believe TSMDA will be an invaluable tool for the community to explore and prioritize potentially new miRNA-disease associations for further experimental characterization. The method was made available as a freely accessible and user-friendly web interface at http:// biosig.unimelb.edu.au/tsmda/.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available